Recently, rarer forms of PD associated with genetic perturbations and mutations in genes encoding for α-synuclein, Parkin, Pink1, and LRRK2 have surfaced and could prove to be potential therapeutic targets. This evidence concerns the gene PRKN and Parkinson disease.